Novartis’ Gene Therapy: A New Era in SMA Treatment Expansion

Novartis has announced that its intrathecal (IT) formulation of onasemnogene abeparvovec (OAV101 IT) met the primary endpoint in the Phase III STEER study involving patients aged 2–17 years with type II spinal muscular atrophy (SMA). These positive results could...